[1] Zarocostas J.Chronic diseases among the over 40s in China are set to double over the next 20 years[J].BMJ,2011,343:d4801.
[2] Wang L,Wang N.HIV/AIDS epidemic and the development of comprehensive surveillance system in China with challenges[J].Chin Med J (Engl),2010,123(23):3495-3500.
[3] Yang W,Lu J,Weng J,et al.Prevalence of diabetes among men and women in China[J].N Engl J Med,2010,362(12):1090-1101.
[4] Supervie V,Ekouevi DK.Overview of the HIV epidemics in France and worldwide[J].Rev Prat,2014,64(8):1060-1066.
[5] Kullberg BJ,Oude Lashof AM.Epidemiology of opportunistic invasive mycoses[J].Eur J Med Res,2002,7(5):183-191.
[6] Liao Y,Chen M,Hartmann T,et al.Epidemiology of opportunistic invasive fungal infections in China:review of literature[J].Chin Med J (Engl),2013,126(2):361-368.
[7] Hahn-Ast C,Glasmacher A,Muckter S,et al.Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006[J].J Antimicrob Chemother,2010,65(4):761-768.
[8] Kontoyiannis DP,Marr KA,Park BJ,et al.Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients,2001-2006:overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database[J].Clin Infect Dis,2010,50(8):1091-1100.
[9] Pagano L,Caira M,Candoni A,et al.Invasive aspergillosis in patients with acute myeloid leukemia:a SEIFEM-2008 registry study[J].Haematologica,2010,95(4):644-650.
[10] Xiao L,Madison V,Chau AS,et al.Three-dimensional models of wild-type and mutated forms of cytochrome P45014alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding[J].Antimicrob Agents Chemother,2004,48(2):568-574.
[11] Cornely OA,Maertens J,Winston DJ,et al.Posaconazole vs.fluconazole or itraconazole prophylaxis in patients with neutropenia[J].N Engl J Med,2007,356(4):348-359.
[12] Raad,II,Hanna H A,Boktour M,et al.Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies:posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin[J].Leukemia,2008,22(3):496-503.
[13] Ziakas P D,Kourbeti I S,Mylonakis E.Systemic antifungal prophylaxis after hematopoietic stem cell transplantation:a meta-analysis[J].Clin Ther,2014,36(2):292-306.
[14] Gomes MZ,Jiang Y,Mulanovich VE,et al.Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia[J].Antimicrob Agents Chemother,2014,58(5):2775-2780.
[15] Girmenia C,Frustaci A M,Gentile G,et al.Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia:a single-center,real-life experience[J].Haematologica,2012,97(4):560-567.
[16] Bourdelin M,Grenouillet F,Daguindau E,et al.Posaconazole prophylaxis in neutropenic patients with hematological malignancies:limits in clinical practice[J].Med Mycol,2014,52(7):728-735.
[17] Desplanques P Y,Burlacu R,Poinsignon V,et al.Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia[J].Med Mal Infect,2014,44(4):174-179.
[18] Greenberg RN,Mullane K,van Burik JA,et al.Posaconazole as salvage therapy for zygomycosis[J].Antimicrob Agents Chemother,2006,50(1):126-133.
[19] Higgins JP,Thompson SG,Deeks JJ,et al.Measuring inconsistency in meta-analyses[J].BMJ,2003,327(7414):557-560.
[20] Chaftari AM,Hachem RY,Ramos E,et al.Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation[J].Transplantation,2012,94(3):302-308.
[21] Shen Y,Huang XJ,Wang JX,et al.Posaconazole vs.fluconazole as invasive fungal infection prophylaxis in China:a multicenter,randomized,open-label study[J].Int J Clin Pharmacol Ther,2013,51(9):738-745.
[22] Ullmann AJ,Lipton JH,Vesole DH,et al.Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease[J].N Engl J Med,2007,356(4):335-347.
[23] De Pauw B,Walsh TJ,Donnelly JP,et al.Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group[J].Clin Infect Dis,2008,46(12):1813-1821.
[24] Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus[J].Clin Infect Dis,2002,34(1):7-14.
[25] Trotti A,Byhardt R,Stetz J,et al.Common toxicity criteria:version 2.0.an improved reference for grading the acute effects of cancer treatment:impact on radiotherapy[J].Int J Radiat Oncol Biol Phys,2000,47(1):13-47.
[26] Colevas A D,Setser A.The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials:6098[J].J Clin Oncol,2004,22 Sup(14):543s.
[27] Skiest DJ,Vazquez JA,Anstead GM,et al.Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection[J].Clin Infect Dis,2007,44(4):607-614.
[28] Walsh TJ,Raad I,Patterson TF,et al.Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy:an externally controlled trial[J].Clin Infect Dis,2007,44(1):2-12.
[29] Pitisuttithum P,Negroni R,Graybill JR,et al.Activity of posaconazole in the treatment of central nervous system fungal infections[J].J Antimicrob Chemother,2005,56(4):745-755.
[30] Kung HC,Johnson MD,Drew RH,et al.Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients:a retrospective cohort study[J].Cancer Med,2014,3(3):667-673.
[31] Sanchez-Ortega I,Patino B,Arnan M,et al.Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation[J].Bone Marrow Transplant,2011,46(5):733-739.
[32] Zoller E,Valente C,Baker K,et al.Development,clinical utility,and place in therapy of posaconazole for prevention and treatment of invasive fungal infections[J].Drug Des Devel Ther,2010,4(4):299-311.
[33] Pfaller M A,Messer S A,Boyken L,et al.In vitro activities of voriconazole,posaconazole,and fluconazole against 4,169 clinical isolates of Candida spp.and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program[J].Diagn Microbiol Infect Dis,2004,48(3):201-205.
[34] Aperis G,Alivanis P.Posaconazole:a new antifungal weapon[J].Rev Recent Clin Trials,2011,6(3):204-219.
[35] Pfaller MA,Messer SA,Rhomberg PR,et al.In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds[J].J Clin Microbiol,2013,51(8):2608-2616.
[36] Restrepo A,Tobon A,Clark B,et al.Salvage treatment of histoplasmosis with posaconazole[J].J Infect,2007,54(4):319-327.
[37] Sabatelli F,Patel R,Mann PA,et al.In vitro activities of posaconazole,fluconazole,itraconazole,voriconazole,and amphotericin B against a large collection of clinically important molds and yeasts[J].Antimicrob Agents Chemother,2006,50(6):2009-2015.
[38] Negroni R,Tobon A,Bustamante B,et al.Posaconazole treatment of refractory eumycetoma and chromoblastomycosis[J].Rev Inst Med Trop Sao Paulo,2005,47(6):339-346.
[39] Segal BH,Barnhart LA,Anderson VL,et al.Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection[J].Clin Infect Dis,2005,40(11):1684-1688.
[40] Vazquez JA,Skiest DJ,Nieto L,et al.A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS[J].Clin Infect Dis,2006,42(8):1179-1186.
[41] Arikan-Akdagli S.Azole resistance in Aspergillus:global status in Europe and Asia[J].Ann N Y Acad Sci,2012,1272:9-14.
[42] Escribano P,Pelaez T,Munoz P,et al.Is azole resistance in Aspergillus fumigatus a problem in Spain[J]?Antimicrob Agents Chemother,2013,57(6):2815-2820.
[43] Giusiano G,Mangiaterra M,Rojas F,et al.Azole resistance in neonatal intensive care units in Argentina[J].J Chemother,2005,17(3):347-350.
[44] Jiang C,Dong D,Yu B,et al.Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China[J].J Antimicrob Chemother,2013,68(4):778-785.
[45] Wang H,Xiao M,Chen SC,et al.In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J].J Clin Microbiol,2012,50(12):3952-3959.
[46] Raad,II,Graybill JR,Bustamante AB,et al.Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections[J].Clin Infect Dis,2006,42(12):1726-1734.
[47] Pagano L,Cornely OA,Busca A,et al.Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases:a report from the SEIFEM and FUNGISCOPE registries[J].Haematologica,2013,98(10):e127-130.
[48] Doring M,Muller C,Johann PD,et al.Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation[J].BMC Infect Dis,2012,12:263.
[49] Perfect JR G D,Corcoran G,Pedicone L,et al.Posaconazole safety and efficacy in elderly patients with invasive fungal infections[M]42nd.Boston,Meeting of the Infectious Diseases Society of America,2004.
[50] Deray G.Amphotericin B nephrotoxicity[J].J Antimicrob Chemother,2002,49(Suppl 1):37-41.
[51] Lestner J,Hope WW.Itraconazole:an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections[J].Expert Opin Drug Metab Toxicol,2013,9(7):911-926.
[52] Marr K A,Crippa F,Leisenring W,et al.Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants[J].Blood,2004,103(4):1527-1533.
[53] Jain L R,Denning D W.The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis[J].J Infect,2006,52(5):e133-137.
[54] Menzin J,Meyers JL,Friedman M,et al.Mortality,length of hospitalization,and costs associated with invasive fungal infections in high-risk patients[J].Am J Health Syst Pharm,2009,66(19):1711-1717.
[55] Maertens J,Marchetti O,Herbrecht R,et al.European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients:summary of the ECIL 3-2009 update[J].Bone Marrow Transplant,2011,46(5):709-718.
[56] Groll A H,Castagnola E,Cesaro S,et al.Fourth European Conference on Infections in Leukaemia (ECIL-4):guidelines for diagnosis,prevention,and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation[J].Lancet Oncol,2014,15(8):e327-340.
[57] Hwang YY,Liang R.Antifungal prophylaxis and treatment in patients with hematological malignancies[J].Expert Rev Anti Infect Ther,2010,8(4):397-404.
[58] 中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第四次修订版)[J].中华内科杂志,2013,52(8):704-709.
[59] Medscape.FDA Clears IV Formulation of Antifungal Posaconazole.http://www.medscape.com/viewarticle/822125.html,2014-06-16. |